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Critically ill patients depend on artificial nutrition for the maintenance of their metabolic functions and lean body
mass, as well as for limiting underfeeding-related complications. Current guidelines recommend enteral nutrition
(EN), possibly within the first 48 hours, as the best way to provide the nutrients and prevent infections. EN may
be difficult to realize or may be contraindicated in some patients, such as those presenting anatomic intestinal
continuity problems or splanchnic ischemia. A series of contradictory trials regarding the best route and timing for
feeding have left the medical community with great uncertainty regarding the place of parenteral nutrition (PN) in
critically ill patients. Many of the deleterious effects attributed to PN result from inadequate indications, or from
overfeeding. The latter is due firstly to the easier delivery of nutrients by PN compared with EN increasing the risk
of overfeeding, and secondly to the use of approximate energy targets, generally based on predictive equations:
these equations are static and inaccurate in about 70% of patients. Such high uncertainty about requirements
compromises attempts at conducting nutrition trials without indirect calorimetry support because the results
cannot be trusted; indeed, both underfeeding and overfeeding are equally deleterious. An individualized therapy is
required. A pragmatic approach to feeding is proposed: at first to attempt EN whenever and as early as possible,
then to use indirect calorimetry if available, and to monitor delivery and response to feeding, and finally to consider
the option of combining EN with PN in case of insufficient EN from day 4 onwards.Introduction
Critical illness requiring vital organ support is generally as-
sociated with an intense inflammatory response and re-
quires bed rest, both factors favoring lean body mass
catabolism. These alterations promote the risk of malnutri-
tion, or aggravate a pre-existing malnutrition, and cause a
related increased morbidity and mortality [1]. Critically ill
patients depend on artificial nutrition for the maintenance
of their metabolic functions and limitation of the under-
feeding related to complications. Delivering adequate
amounts of nutrients and energy should therefore be a
basal preoccupation of the intensivist, like hydration and
pain control. Giving your patient a FAST HUG (feeding,
analgesia, sedation, thromboembolic prophylaxis, head-
of-bed elevation, stress ulcer prophylaxis and glycemic
control) is exactly this provision of basal care [2].* Correspondence: mette.berger@chuv.ch
1Service de Médecine Intensive Adulte et Brûlés, Lausanne University
Hospital (CHUV), 1011 Lausanne, Switzerland
Full list of author information is available at the end of the article
© 2014 Berger and Pichard; licensee BioMed C
medium, for 12 months following its publicatio
Attribution License (http://creativecommons.org
in any medium, provided the original work is p
(http://creativecommons.org/publicdomain/zeroCurrent guidelines recommend early enteral nutrition
(EN) as the best way to provide the nutrients [3,4].
Nevertheless, EN is a technique associated with practical
problems worldwide, resulting in frequent insufficient
feed delivery [5]. Further, EN may be contraindicated in
some patients, such as those presenting anatomic intes-
tinal discontinuity or splanchnic ischemia; hard contra-
indications are not very frequent in our experience,
varying between 5 and 7% in the Geneva and Lausanne
ICUs. Intravenous administration of macronutrients and
micronutrients, called parenteral nutrition (PN), becomes
recommended under certain circumstances (Table 1) [6]
and is technically easier to deliver than EN. PN has there-
fore been overused in many ICUs, and has been associated
with both metabolic and infectious complications [7]. In
2013 the medical community is left with great uncertainty
regarding the place of PN in critically ill patients.
This review aims at summarizing some critical meta-
bolic changes in critically ill patients, and at explaining
the historical background of PN development that im-
pacts on its actual strengths and weaknesses.entral Ltd. The licensee has exclusive rights to distribute this article, in any
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Table 1 Indications for parenteral nutrition




Abdominal distension on enteral nutrition
• Short bowel syndrome
Mesenteric infarction
Extensive small bowel resection leaving <1.5 m
• Severe malabsorption
Radiation injury to the intestine
High output fistulae (jejunal > ileal)
Inflammatory bowel diseases in acute phase
Splanchnic ischemia
• Time to reach full enteral nutrition or oral >5 days
• Insufficient energy intakes
• Hyperemesis gravidarum
• High risk of aspiration
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Critical illness elicits a cascade of inflammatory, im-
mune, endocrine and metabolic responses [8]. Critically
ill patients are generally considered to be hypermeta-
bolic, with exacerbated lipolysis, proteolysis and extra-
cellular water gain associated with fluid resuscitation [9].
In response to inflammatory mediators and oxidative
stress, and particularly in patients remaining acutely ill
beyond the first 72 hours, proteolysis increases massively
in excess of protein synthesis, a condition called catabol-
ism that causes a rapid loss of lean body mass, mostly
controlled by the ubiquitin–proteasome pathway [10].
In the 1990s, using stable isotope techniques, it was
shown that energy and protein requirements were higher
in critically ill patients than in healthy subjects. Isocaloric
PN was also shown to be well tolerated without generating
undue hyperglycemia, but exceeding 1.3 g protein/kg/day
intakes did not further increase protein accretion [11]
(Figure 1). In critically ill trauma patients, PN providing
120% of the measured energy expenditure (EE) did not
have any positive effect on protein metabolism, but only
generated deleterious hypermetabolism [12]. Further, bed
rest studies conducted by the European Space Agency
demonstrated an intense protein catabolism related to
physical immobilization [13], the latter being increased by
hypocaloric feeding.
Critically ill patients combine both intense stress and
physical immobilization [13] that may cause a rapid de-
crease of lean tissues, which in turn has an impact on re-
spiratory and peripheral muscle function. After an acute
disease, recovery of the muscle alterations is associated
with an improved global functioning and quality of life[15]. The preservation of lean body mass appears par-
ticularly important for the final outcome. Optimal nutri-
tion support during critical illness has been postulated
to limit protein catabolism and promote faster recovery,
although this concept has been challenged recently in
a substudy of patients from the large Early Parenteral
Nutrition Completing Enteral Nutrition in Adult Critic-
ally Ill Patients (EPaNIC) trial: PN administered from
admission to the ICU as glucose followed by PN did
not prevent lean body mass loss [16]. Contrasting with
these results, an Australian study enrolling 1,372 pa-
tients with a short-term contraindication for EN showed
clinical benefits in patients randomized to early PN with
shorter mechanical ventilation and a better quality of
life at 2-month follow-up; the parenteral intervention of
course resulted in a better protein coverage compared
with standard care [17]. More data on long-term out-
come are needed.
Historical development
Considering the development of PN is helpful in under-
standing the actual controversies. Figure 2 summarizes
the major steps in the history of PN. Although attempts at
feeding intravenously can be found as early as the 16th
century, complete PN in its modern form was invented by
Arvid Wretlind and colleagues in 1961 in Sweden [18]
and in the USA [19]. From the start, this feeding tech-
nique saved many lives compromised by gastrointestinal
failure, previously doomed to rapid death. Since its enthu-
siastic start in the 1960s, PN has evolved tremendously
and has generated numerous contradictory publications.
Today, the production of metabolically balanced
amino acid (AA) combinations remains a challenge. The
development of the crystalline AAs [21] led to a better
tolerance, but more prolonged PN treatments unmasked
trace element deficiencies, requiring the development of
balanced micronutrient solutions to compensate deficits
resulting from the purification of the AA solutions.
The lipid emulsions remained the most difficult issue
during decades. Severe complications of the cottonseed-
derived lipid emulsions were observed in the USA, where
their withdrawal led to incomplete PN (that is, without
lipids) for decades. In Europe, however, thanks to the ex-
istence of the soybean solution using egg yolk phospho-
lipids as an emulsifying agent, PN was complete (total
PN) from the start. PN was widely used, often in patients
without gastrointestinal failure, and despite the central
venous access-associated complications. It is indeed much
easier to deliver the prescribed amount of energy by the
intravenous route than by the enteral route [22].
In the 1970s and 1980s the observation of devastat-
ing losses of lean body mass was the rationale for
the delivery of hyperalimentation, as feeding was first
called, using large glucose loads, erroneously supposed
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Figure 1 Effect of nutrition support on total body protein in patients with an acute flare of ulcerative colitis. Conversely to patients with
standard care (broken line; mean age 47.6 ± 12.1 years, mean weight 59.4 ± 12.5 kg), ulcerative colitis patients with total parenteral nutrition
(TPN; solid black line; mean age 42.6 ± 10.2 years, mean weight 60.8 ± 10.6 kg) received TPN from hospital admission until day 14 after surgery.
Patients without TPN showed a rapid body protein loss that fell under the critical threshold before hospital admission, and worsened during the
perioperative period. On the contrary, TPN prevented the worsening of protein body loss during the perioperative period and was associated
with an earlier restoration (18 weeks earlier) of normal protein stores (mean ± standard deviation). Reproduced with permission from [14].
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to prevent AA loss. The glucose–protein sparing strategy
and the unavailability of lipid emulsions in the USA led to
the prescription of high doses of dextrose exceeding the
oxidizing capacity. Delivering >3,000 kcal/day was very







Figure 2 Milestones in the development of artificial nutrition. Develop
amino acid and glucose steps (right). Adapted with permission from [20].15 mmol/l was considered adaptive, and was generally not
treated. The high glucose loads generated complications
(excessive carbon dioxide production, respiratory failure,
fever, additional metabolic stress, liver steatosis) [23]. It
became obvious that parenteral hyperalimentation caused
increased infectious complications compared with EN,ment steps in energy requirements and lipid emulsions (left) and
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Leuven trial did the medical community become aware of
the importance of controlling blood glucose levels by
means of continuous insulin therapy [25], although the
NICE SUGAR and Glucontrol trials subsequently demon-
strated that intensive insulin therapy was potentially dan-
gerous [26,27] and that less strict glucose targets compared
with the initial normoglycemia (4.1 to 6 mmol/l) used by
the Leuven team were safer.
Fong and colleagues showed that 5 days of PN in
healthy subjects compared with EN exacerbated the
inflammatory response to endotoxin [28]. In 1991 the
Veterans study showed an absence of benefits and even
deleterious effects of perioperative PN in patients without
malnutrition [24]. These trials nearly destroyed the con-
cept of PN, given that clinicians became very suspicious
about potential deleterious consequences.
In the 1990s, technical advances in plastics enabled the de-
velopment of double-compartmental and tri-compartmental
bags in Europe, with separation of the macrosubstrates
during storage, being easy to handle, and providing the
necessary guaranties regarding stability and sterility of
the solutions, reducing contamination, errors in pre-
scription, and costs [29].
Energy requirements
Determination of the patients’ energy and substrate re-
quirements has proven much more difficult than ex-
pected. Evolving from the early phase of systematic
hyperalimentation, the promotion of EN as the only cor-
rect way to feed patients has generated a second wave of
ICU hypoalimentation from the 1990s that still persists
[5,30,31]. A large proportion of severely ill patients leave
the ICU with a cumulated deficit of up to 10,000 to
20,000 kcal [5,30,31], which roughly corresponds to
about 5 to 10 kg lean tissues and 0.5 to 1 kg fat reserve.
The guidelines have tried to promote a reasonable ap-
proach recommending 20 to 25 kcal/kg body weight in
the early acute phase, to be increased to 25 to 30 kcal/kg
in stabilized patients [6]. The aim was to initiate feeding
early (that is, during the first 48 hours), preferentially by
EN, to prevent the addition of an energy deficit to a pre-
viously malnourished patient or to avoid worsening the
catabolic response of stress patients.
The problem with all energy predictive equations is
that they fail in nearly 70% of patients [32,33], being to-
tally unreliable in the obese but also at the other end of
the spectrum in patients with low body mass index <18.
This unreliability occurs because EE in critically ill pa-
tients is highly variable depending on the initial injury,
severity of the disease, nutritional status, time after
admission and treatments, and an unpredictable vari-
ation of the body weight to EE ratio [34]. Many pro-
posed equations are based on static variables (sex, age,weight, height) while others include dynamic variables
(fever, minute ventilation, heart rate) [35]. Indirect calor-
imetry is considered the gold standard for determining
EE, enabling feeding to be adapted to the measured EE.
Two equations have been derived from such measure-
ments and perform better than others: the Faisy–Fagon
equation for mechanically ventilated patients [36], and
the Toronto equation for major burns [37]. Figure 3
shows two static equations that failed to provide ad-
equate orientation on the real energy target in the Swiss
supplemental parenteral nutrition (SPN) trial compared
with indirect calorimetry [38].
The tight calorie control study (TICACOS) is among
the rare ICU studies where EE has been systematically
and repeatedly measured, being determined every sec-
ond day [41]. Unfortunately, the prescription of energy
did not integrate non-nutritional calories (that is, associ-
ated with glucose for drug administration or lipid from
propofol) despite supervision by the research team, and
resulted in systematic overfeeding in the intervention
group, which is likely to explain the observed increasing
incidence of pneumonia and prolonged ventilation. Des-
pite these immediate ICU complications, the TICACOS
also showed that a better energy coverage in the calor-
imetry group with a combined nutrition support resulted
in a reduced length of hospital stay and hospital mortal-
ity, but the numbers were too low to allow for definitive
conclusions, needing repetition and extension of the
study. Recently, the SPN trial showed that this individu-
alized energy supply obtained by EE measurement in
65% of patients was rewarding in terms of reduction of
nosocomial infections in severely ill ICU patients requir-
ing prolonged ICU treatment [38]. Grau and colleagues
have shown that liver alterations (defined as cytolysis,
cholestasis or a combination of both) during enteral or
parenteral feeding occur frequently if energy delivery
exceeds 27 kcal/kg/day, and add to those liver alter-
ations caused by sepsis and multiple organ failure [42];
the difference becomes significant after day 11 in pa-
tients on PN, ED producing less alteration related to
lower energy intakes.
Hypocaloric feeding: a real option?
Overfeeding is a threat, so some authors have proposed
prescribing hypocaloric feeding; that is, 70 to 80% of
the calculated target [43]. This strategy has been mainly
developed for obese patients, in whom all of the equations
invariably fail; the Penn State equation adapted for obese
patients being among the closest to measured EE [44]. By
contrast in hemodynamic management, an underprescrip-
tion of norepinephrine would not be a treatment option
in case of an arterial hypotension. Similarly, we need to
prescribe what is considered adequate and optimal re-
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Figure 3 Relationship between two commonly used equations and the value of energy expenditure. Indirect calorimetry study on day 3
shows that both equations overestimated and underestimated energy expenditure in an unpredictable manner. (A) Pre-enrollment target 25 to
30 kcal/kg actual body weight (BW): arrows show the relation between the calculated energy target used for enrollment (25 or 30 kcal/kg/day)
and the measured energy expenditure that became the target used from day 4. (B) Target of the supplemental parenteral nutrition patients
recalculated using an equation based on a corrected ideal body weight, age and gender [39], which was used in the Early Parenteral Nutrition
Completing Enteral Nutrition in Adult Critically Ill Patients (EPaNIC) trial [40] (corrected ideal body weight, age and gender [34] + absolute maximal
target of 2,880 kcal).
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of calories further lowers the protein delivery – a mini-
mum energy is required to be able to benefit from pro-
teins [9]. Moreover the international surveys show that
underfeeding remains a serious threat [5], while patients
with body mass index <18 experience a maximal vari-
ability of energy delivery.
Recent research has focused on autophagy, which be-
longs to the healing process as removal of mitochondria
damaged during the acute phase of sepsis. This mechan-
ism is a two-edged sword, however, which may cause cell
death [45]. Insulin is a well-documented inhibitor of
autophagy [46]. Overfeeding leads to increased insulin
requirements to achieve blood glucose control. In the
EPaNIC trial [16], the patients in the early PN group
needed nearly double the amount of insulin for this pur-
pose, probably reflecting overfeeding that was associated
with depressed autophagy. Figure 3B shows that the
“Leuven” equation results in frequent excessive targets
when EE is verified by indirect calorimetry. By contrast,
feeding in the SPN trial was guided by calorimetry, and
no such increase was observed with identical insulin re-
quirements in both arms [38].
From substrate provision to pharmaconutrition
Amino acids
The first crystalline AAs were unbalanced, containing
about 50% glycine of low biological value. Introducing
tyrosine, cysteine–cystine and glutamine was technically
difficult due to stability and solubility problems. Glutam-
ine was finally solubilized under the dipeptide formglutamine–alanine by Fürst and Stehle [47]. The concept
of conditionally essential AAs emerged in this period;
these are AAs that are supplied by food and synthesized
under normal conditions but which during critical ill-
ness become deficient because of insufficient supply
and increased consumption. Isolation of various AAs
led to the possibility of using them separately, poten-
tially as drugs.
Glutamine, the most abundant free AA in the body,
which constitutes over 60% of the muscle free AA pool
[47], is one of these conditionally essential AAs; deple-
tion has repeatedly been shown to occur in critically ill
patients and is associated with poor prognosis [48].
Well-conducted repletion studies have shown that glu-
tamine administration is beneficial if administered along
with an optimized nutrition therapy, particularly by the
parenteral route, improving glucose control and achiev-
ing reduction of both infectious complications and mor-
tality [49-52]. But glutamine cannot be provided in
standard PN for stability reasons, which increases the
risk of deficiency.
Two recent large prospective randomized clinical trials
brought confusion, the doses of glutamine and their tim-
ing largely explaining the negative results. The Scottish
SIGNET trial enrolled 502 patients with gastrointestinal
failure [53]. The patients were randomized to receive daily
20.2 g glutamine or 500 μg selenium, or both, versus pla-
cebo for up to 7 days. There was no overall effect of glu-
tamine on new infections or on mortality, while selenium
was associated with less infectious complications if deliv-
ered for longer than 5 days. Several shortcomings of the
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one-size-fits-all prescription of the ready-to-use PN bags,
resulted in the delivery of a very low glutamine dose
(0.1 g/kg/day) for a very short period, far below inter-
national recommendations [6]. On the non-effect side, a
small American prospective randomized clinical trial in 44
patients randomized to three groups receiving either iso-
nitrogenous enteral nutrition or 0.5 g/kg/day glutamine by
the intravenous or enteral route for 8 days showed no dif-
ference in antioxidant status or other markers of oxidative
stress [54]; importantly, about one-third of the patients
had normal baseline glutamine levels.
The REDOXS trial reports data for 1,223 patients re-
ceiving the highest doses so far used of glutamine
(0.78 g/kg/day supplied as 0.35 g/kg intravenously +
30 g/day enterally), about twice the recommended doses,
in patients with severe organ failure (93% of patients in
shock state and 33% with renal failure) starting within
the first 24 hours of admission independently of nutri-
tion [55]; that is, earlier than any previous trial. In
addition, the glumatine group suffered more organ fail-
ure which might explain on its own the higher mortality.
Surprisingly, in a subset of patients with plasma deter-
mination, only 31% of patients presented with a low
baseline glutamine level (<420 μmol/l) whereas 15% of
these patient had supranormal plasma glutamine values
at baseline. The latter finding has been shown to be as-
sociated with increased mortality [56]. Pharmacological
doses of glutamine in unstable patients are therefore to
be avoided.
Lipids
Many of the early problems as well as the progress of
PN were associated with the development of lipid emul-
sions [23]. Prolonged use of the glucose and AA-based
formulations with no fat was associated with essential
fatty acid deficiency [23]. As fatty acids are more energy
dense (about 9 kcal/g) than both AAs (4 kcal/g) and glu-
cose (3.7 kcal/g), they enable reducing both the fluid
load (important in the ICU patient) and the osmolarity
of the solutions, permitting peripheral administration in
some patients.
Since the development of the long-chain triglyceride so-
lution by Wretlind and colleagues, major developments
have occurred (Figure 2). Pulmonary and hematological
side effects were observed, as well as an enhanced oxi-
dative stress causing peroxidation of the unsaturated
fatty acids; the latter may cause cell death and worsen-
ing of organ failures [21]. One of the first options aim-
ing at minimizing oxidative stress was to partially
replace polyunsaturated fatty acids (PUFAs) with oils
rich in medium-chain triglycerides derived from coco-
nut oil, which are less prone to peroxidation. Another
advantage of medium-chain triglycerides is that theyrequire less carnitine for mitochondrial penetration
than long-chain triglyceride solution and are metabo-
lized more rapidly, but they increase in a reversible
manner the production of ketone bodies [57].
Progressively, it became obvious that the various PUFAs
have proper modulating effects on the inflammatory re-
sponse [58]. Medium-chain triglycerides and monoun-
saturated fatty acids derived from olive oil are considered
the most neutral, while the more recently developed n-3
PUFAs derived from fish oil exhibit anti-inflammatory
properties [58]. The intravenous administration of n-3
PUFAs seems associated with clinical benefits [59] and
quick physiological effects [60]; development is ongoing
and has been reviewed recently [61].
Is parenteral pharmaconutrition worth it?
These variable results have lead to questioning the cost-
efficiency resulting from glutamine and n-3 PUFA ad-
ministration. The most convincing evidence comes from
recent large-scale medico-economic studies. A large re-
cent Italian study in 60,000 patients from 200 Italian
ICUs strongly supports the use of glutamine containing
PN [62]; the costs of treatment were completely offset
by savings made by shortening the ICU stay and lower
antibiotic costs. Similarly regarding n-3 PUFAs, an ana-
lysis including 23 trials in 1,502 patients showed that
n-3 PUFA inclusion in PN resulted in a reduction of in-
fection complications (relative risk = 0.61) and of lengths
of stay [63], both in the ICU (nearly 2 days) and in the
hospital overall (3.3 days), reducing the costs. Finally, an
economic analysis of the Australian early PN study
showed that the strategy of cautious early PN reduces
hospital costs [64]. Well-conducted nutrition therapy,
despite including a modest investment, is cost-saving in
the end.
What is the optimal timing for parenteral
nutrition introduction?
While the indications for total PN (delivery of glucose,
proteins, fat, and micronutrients) are unchanged, much
controversy has arisen regarding its timing. Guidelines
have been understood in divergent ways: the European
Society of Clinical Nutrition PN guidelines have been
interpreted as ‘deliver PN after 2 days’ [6], while the
American Society of Parenteral and Enteral Nutrition
guidelines have been understood as ‘no feed before day
7’ [65].
The large, prospective, EPaNIC trial randomized 4,640
patients to early PN (2 days with glucose from day 0)
followed by full PN versus late PN (day 8) after ICU ad-
mission, and concluded that early PN was harmful, with
later ICU discharge and more complications (including
infections), despite the application of a tight glycemic
protocol [40]. The EPaNIC trial used PN in unselected
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the major pitfalls of the study; early PN in low-risk pa-
tients may be harmful [66], confirming the Veterans trial
results [24]. McClave and colleagues pinpointed various
limitations of the study, such as the hypercaloric and
low nitrogen intakes and the over-representation of car-
diovascular surgery patients, which reduce its external
validity [66].
The Swiss SPN prospective randomized controlled
trial enrolled 305 patients on day 3 of admission to the
ICU: enrollment criteria were that patients received ≤60%
of the calculated energy target from EN, were expected to
stay for >5 days, and were expected to survive for >7 days
[38]. All patients were given a chance to be fed enterally,
only those failing to achieve 60% of target were random-
ized to receive, or not, supplemental PN on top of EN in
order to cover their measured energy needs after day 3.
Energy targets were set by indirect calorimetry after day
3 (Figure 3A) or, if not technically possible, continued
as 25 and 30 kcal/kg actual body weight/day for women
and men, respectively. The difference between the in-
direct calorimetry value and the equation target varied
between −1,000 and +1,000 kcal/day. Figure 3 shows the
relation between these measurements and two commonly
used equations: the simple 25 to 30 kcal/kg body weight
equation [6], and a more sophisticated equation based on
the corrected ideal body weight, age and gender [39] used
in the EPaNIC trial. Patients were randomly assigned to
continue exclusive EN or to SPN (EN + PN). The primary
outcome was the occurrence of nosocomial infection
from the end of intervention (day 8) until the end of the
follow-up (day 28). The intervention group had less
nosocomial infections (P = 0.03), and a lower meanTable 2 Suggestions for a systematic weekly monitoring of m
changes
Variable Mon Tue Wed Thu Fri Sat Su
Energy balance (daily, accumulated) X X X X X X X
Glucose 4 4 4 4 4 4 4
Insulin/24 hours X X X X X X X
Triglycerides 1 1
ASAT ALAT 1 1
Prealbumin 1
Albumin CRP 1
Weight (actual) X (X)
Se, zn ?
CRP, C-reactive protein; CRRT, continuous renal replacement therapy; ?, on demandnumber of nosocomial infections and of antibiotic days
per patient, resulting in more antibiotic-free days. The
study concluded that individually optimized energy sup-
plementation with SPN starting 4 days after ICU admis-
sion could reduce nosocomial infections. The study has
some shortcomings that are summarized in a series of
letters [67a-d], particularly the fact that infections during
the intervention were not considered. But indeed the pri-
mary endpoint was infections after the intervention (5 days
of full feeding). The difference became only significant
after a few days, a time delay that appears to be normal
for a metabolic intervention that requires 3 to 5 days
to become measurable, distinguishing nutritional therapy
from pharmacological interventions. Under conditions of
insufficient EN, SPN might improve clinical outcome, if it
adequately covers basal energy requirements, enabling a
normal metabolic response.
Doig and colleagues enrolled 1,372 Australian patients
with a temporary contraindication to EN in an early PN
trial [68]. The patients were randomized within 24 hours
of ICU admission to receive either standard care or early
PN. Their conclusion is that ‘the provision of early PN
to critically ill adults with relative contraindications to
early EN, compared with standard care, did not result in
a difference in day-60 mortality. The early PN strategy
resulted in significantly fewer days of invasive ventilation
but not significantly shorter ICU or hospital stays’ [68].
The deleterious effects observed in the EPaNIC trial
were not observed in the early PN group, which sup-
ports the findings in the SPN trial [38]; indeed, the en-
ergy targets used in the Australian trial were modest,
based on the Harris and Benedict equation, thereby re-
ducing the risk of overfeeding.etabolic response to feeding, with interpretation of the
n Mon Interpretation
X Daily delivery >110% or <80% of prescription:
act accordingly to ↓ or ↑ intake
Cumulated energy target over 3 to 6 days: <−4,000 kcal,
beware and increase feeding; <−8,000 (−100 kcal/kg), danger
4 ↑: suspect overfeeding or infection; →, continue as is;
↓, improving condition
X
1 ↑: non-nutritional fat intake? Nutritional fat? Sepsis?
1 ↑: sepsis? Drug toxicity? Overfeeding? Watch for glucose.
→, continue
1 ↑: decreased inflammation and improved protein accretion;
↓: worsening of inflammation or insufficient protein intakes
1 Provide information on level of inflammation and severity
of disease
X ↑: fluid accumulation? ↓: loss of fluid and lean body mass
In at-risk patients (CRRT, intestinal fistulae, prolonged feeding)
in patients considered at risk.
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shown by a recent trial including 1,595 ICU patient-days.
EN may contribute to development of diarrhea because
the delivery of more than 60% of the energy expenditure
almost doubled the risk of diarrhea. This suggests that in
some patients the combination of EN and PN may be
helpful, reducing the burden and the cost of managing
diarrhea (manpower, investigations, treatment) [69].
How to monitor artificial feeding and parenteral
nutrition
The clinical follow-up should integrate a close monitoring
of the metabolic and gastrointestinal tolerance with a
bundle combining clinical observations, a daily glycemic
profile and insulin requirements to watch for potential
overload. Monitoring should also include a weekly labora-
tory workout and observations of the changes over time of
these variables (Table 2).
Towards a pragmatic approach
These trials are showing us the way to a reasonable nutri-
tional therapy. Our aim is still to counteract a massive ca-
tabolism, but all patients are not equally exposed to this
risk. The critically ill patient is an individual to whom
mean values apply poorly. Energy equations are simple to
calculate, but constitute an inadequate tool; measuring the
individual requirement is essential to avoid both under-
feeding and overfeeding. Starting EN within the first
48 hours at a slow progressive rate (20 ml/hour even in
the sickest) is beneficial, including for non-nutritional rea-
sons such as keeping bowel motility and IgA secretion [4].
If the gut is not functional with a transient or permanent
contraindication to EN, a precise PN with low targets
covering only the basal resting EE requirements, mea-
sured or based on the crude Harris and Benedict equa-
tion, may be initiated after 2 to 3 days in those patients
presenting malnutrition on admission [68]. On the
other hand, early overfeeding is deleterious, and is a real
risk with PN [40]. After day 3, if the EN does not cover
the measured expenditure, then a combined intravenous
and enteral approach may prevent larger energy deficits
[38]; the tolerance level to energy deficit seems to be some-
where around a cumulated balance of −50 to −80 kcal/kg
body weight from admission before development of
complications related to underfeeding. The concept im-
plies a monitoring of feeding delivery to closely guide
nutrition therapy.
An unequivocal approach – that is, one opposing en-
teral and parenteral feeding – is inadequate in most ICU
patients [70]. However, a pragmatic and reasonable atti-
tude seems the better deal for the individual patient;
while PN is simpler to deliver than EN, its metabolic
consequences are more complicated to handle. The au-
thors’ experience is that PN requires tight monitoringand dedicated resources such as dieticians in the ICU
[71]. PN saves lives, but easily causes overfeeding, with
its deleterious side effects. We have to work at identify-
ing and measuring needs more precisely, but also ob-
serving the individual tolerance to enteral or parenteral
feeding, in order to optimize the global care of patients.
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